











- 2) Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, Zhu J, Zhang Q, Wu J, Liu L. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. *J Med Virol.* 2020 Jun;92(6):595-601. doi: 10.1002/jmv.25726.
- 3) Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? *Eur J Clin Pharmacol.* 2020 Nov;76(11):1615-1618. doi: 10.1007/s00228-020-02947-4.
- 4) Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, Usmani AM, Hajjar W, Ahmed N. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. *Eur Rev Med Pharmacol Sci.* 2020 Feb;24(4):2012-2019.
- 5) Ferrara, F. Antirheumatic in SARS-CoV-2: benefit or risk?. *Italian Journal of Medicine.* 2020; 14(2), 114-115. <https://doi.org/10.4081/itjm.2020.1290>.
- 6) Vitiello A, Ferrara F, Pelliccia C, Granata G, La Porta, R. Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia. *Italian Journal of Medicine.* 2020; 14(2), 88-94. <https://doi.org/10.4081/itjm.2020.1284>
- 7) Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Front Med.* 2020 Apr;14(2):185-192. doi: 10.1007/s11684-020-0754-0.
- 8) Batlle D, Wysocki J, Satchell K. Soluble angiotensin converting enzyme 2: a potential approach for coronavirus infection therapy? *Clin Sci (Lond).* 2020 Mar 13;134(5):543-545. doi: 10.1042/CS20200163.
- 9) Tan WSD, Liao W, Zhou S, Mei D, Wong WF. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases. *Curr Opin Pharmacol.* 2018 Jun;40:9-17. doi: 10.1016/j.coph.2017.12.002.
- 10) Patel S, Rauf A, Khan H, Abu-Izheid T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. *Biomed Pharmacother.* 2017 Oct;94:317-325. doi: 10.1016/j.biopha.2017.07.091.
- 11) Vitiello A, Ferrara F. Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 Infection.. What do we know?. *Eur J Pharmacol.* 2020;883:173373. doi:10.1016/j.ejphar.2020.173373.
- 12) Vitiello A, Ferrara F. Therapeutic Strategies for SARS-CoV-2 acting on ACE-2 [published online ahead of print, 2020 Sep 30]. *Eur J Pharm Sci.* 2020;156:105579. doi:10.1016/j.ejps.2020.105579.
- 13) Vitiello A, Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. *Life Sci.* 2020;262:118510. doi:10.1016/j.lfs.2020.118510.
- 14) Vitiello A, La Porta R, Ferrara F. Sacubitril, valsartan and SARS-CoV-2. *BMJ Evid Based Med.* 2020 Jul 27;bmjebm-2020-111497. doi: 10.1136/bmjebm-2020-111497.
- 15) Mirabito Colafella KM, Bovée DM, Danser AHJ. The renin-angiotensin-aldosterone system and its therapeutic targets. *Exp Eye Res.* 2019;186:107680. doi: 10.1016/j.exer.2019.05.020.
- 16) Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. *Drug Dev Res.* 2020 Aug;81(5):537-540. doi: 10.1002/ddr.21656.
- 17) Ferrara F, Porta RL, D'Aiuto V, Vitiello A. Remdesivir and COVID-19. *Ir J Med Sci.* 2020. E-pub. doi: 10.1007/s11845-020-02401-5.